Abstract: A series of amido-substituted triazolopyrrolo[2,1-c][1,4]benzodiazepine (PBDT) derivatives was synthesized from isatoic anhydride, and their cytotoxicity against the MRC-5 and Mahlavu cell lines was evaluated. The results suggest that compound PBDT-7i with the meta-trifluoromethylbenzoyl substituent can selectively inhibit the growth of Mahlavu cells and has low toxicity towards MRC-5 cells.
Introduction
Cancer is a leading cause of death globally, accounting for 7.6 million deaths in 2008. Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and occurs at a high rate (3-5% annually) in patients with chronic viral hepatitis and cirrhosis. HCC is also a major cause of morbidity and mortality in patients with advanced liver disease [1, 2] . Therefore, there is a desire to design and develop more potent therapeutic agents for cancer. We are interested in investigating N-bridged heterocycles composed of two bioactive heterocyclic moieties, such as benzodiazepines and triazoles, in a single molecular scaffold because such bridged molecules are endowed with a variety of biological activities and have a wide range of therapeutic properties.
Among pharmacologically important heterocyclic compounds, benzodiazepines are useful scaffolds that are widely applied for various therapeutic purposes [3] [4] [5] [6] [7] [8] . Pyrrolo [2,1-c] [1, 4] benzodiazepines (PBDs) are found in natural antitumor antibiotics isolated from Streptomyces species; these natural antitumor antibiotics include anthramycin (1), tomaymycin, chicamycin A, DC-81 (2), mazethramycin, abbeymycin (3), neothramycin A and B and porothramycin B ( Figure 1 ) [9] . PBDs can recognize and bind to specific DNA sequences and are potential regulators of gene expression. These compounds have possible applications as therapeutic agents for the treatment of genetic disorders including cancer [10] . Benzodiazepines made up of fused tri-and tetraheterocyclic rings have attracted attention in the area of medicinal chemistry; midazolam (4), flumazenil and estazolam (5) have attracted attention in the area of CNS disorders, and bretazenil (6) has emerged for the treatment of neurodegenerative diseases [11] [12] [13] [14] [15] (Figure 1 ). In addition, 1,2,4-triazole and its derivatives are being used in a variety of therapeutic applications due to their antibacterial, antifungal, anticancer, antitumor, anticonvulsant, anti-inflammatory and analgesic properties [16, 17] . 1,2,4-Triazoles fused with other heterocyclic moieties possess a broad spectrum of biological activities [18] .
Owing to the biological significance of these two classes of compounds, we planned to synthesize a combined molecular framework. We report herein the synthesis of tetracyclic triazolopyrrolo [2,1-c] [1,4]benzodiazepines (PBDTs) and their amido-substituted derivatives. The cytotoxicity of the newly synthesized derivatives was investigated using the Mahlavu (human hepatocellular carcinoma) and MRC-5 (normal human fibroblast) cell lines.
Results and Discussion

Synthesis
The synthesis strategy for constructing the tetracyclic 1-amido-substituted triazolopyrrolo[2,1-c] [1, 4] benzodiazepin-8-one derivates PBDT-7a-k is shown in Scheme 1. The key intermediate 11 was prepared in four steps. First, pyrrolo-benzodiazepinedione 8 was obtained by the cyclocondensation of L-proline with isatoic anhydride. The corresponding mono-thiolactam 9 was produced by thiation employing Lawesson's reagent in toluene at 70 °C [19] . Subsequently, the thiolactam 9 was converted into 11-hydrazinopyrrolo[2,1-c] [1, 4] benzodiazepine (10) using hydrazine hydrate in ethanol at rt, and cyclization with cyanogen bromide afforded the triazolo PBD 11 [20, 21] . Then, a series of amido-substituted triazolo-fused PBDs (compounds PBDT-7a-k) was synthesized from the tetracyclic intermediate 11 by coupling these molecules with the corresponding carboxylic acids using HATU as a coupling agent in the presence of Hünig's base (Table 1) . 
Cytotoxicity
The cytotoxic activities of the newly synthesized amido-substituted triazolopyrrolo Our initial results showed that percentages of viable Mahlavu and MRC-5 cells exposed to the compounds PBDT-7a,b and PBDT-7j,k were above 75%, although the concentration was increased to 100 µM. This revealed that the aliphatic and aromatic amides seem no significant difference observed in cytotoxicity between Mahlavu and MRC-5 cell lines. Intriguingly, cells exposed to compounds with various substituents [-F (PBDT-7c-e), -OMe (PBDT-7f), -CN (PBDT-7g), -Cl (PBDT-7h) and -CF 3 (PBDT-7i)] on the phenyl ring of the PBDT exhibited different viabilities for both cell lines. Compounds with the fluoro substituent at various positions (compounds PBDT-7c-e) exhibited different levels of toxicity against Mahlavu and MRC-5 cells. The viability of Mahlavu cells exposed to the compound with a fluoro substituent at the meta-position (compound PBDT-7d) was approximately 61% at 100 µM, whereas the ortho-and para-fluoro-substituted compounds PBDT-7c and e had little effect at the same concentration.
Based on the preliminary results, we selected to further investigate the meta-position of the phenyl group (compounds PBDT-7f-i). The cell viabilities were reduced in the presence of the chloro-substituted PBDT-7h in a dose-dependent manner, and the survival rate of Mahlavu cells was below 50% at 50 µM. PBDT-7h was a potent inhibitor of Mahlavu cells, but was also highly toxic for normal cells. To increase the specificity, we evaluated other three meta-substituted PBDTs, including compounds with the -OMe (PBDT-7f), -CN (PBDT-7g) and -CF 3 (PBDT-7i) substituents. It should be noted that the cell viabilities of Mahlavu cells were decreased to 37%, 36%, and 2% at 100 µM, respectively, and the IC 50 values of PBDT-7g and PBDT-7i were 50 µM for Mahlavu cells. These compounds were slightly toxic to MRC-5 cells, with cell viabilities above 70% at 50 µM. These revealed compound PBDT-7i with the meta-trifluoromethylbenzoyl substituent can selectively inhibit the growth of Mahlavu cells and is low-toxic to MRC-5 cells. This novel compound certainly deserves further careful investigation to determine its mechanism of action. 
Experimental
General
Melting point (mp) determinations were performed by using a Mel-temp apparatus and are uncorrected. 1 H-and 13 C-NMR spectra were recorded in DMSO-d 6 (unless otherwise specified) on a Varian Unity instrument at room temperature at 400/100 MHz, respectively. Chemical shifts are reported in δ parts per million (ppm) downfield from tetramethylsilane (TMS) with reference to internal solvent and coupling constants are expressed in Hz. Mass spectra were obtained on a Micromass QuattroMicro TM API-autospectrometer using the APCI technique. HRMS TOF-ES mass spectra were recorded on a Waters-Alliance 2695 Separation Module/Q-TOF Micromass. Infrared (IR) spectra (KBr disks) were recorded on a Perkin Elmer FT-IR spectrometer. Optical rotations ([α] D ) were measured on a JASCO P-1030 polarimeter. Liquid chromatography-mass spectrometry (LCMS) data was generated on a Waters acquity UPLC photodiode array detector (PDA) system using the ESI technique. (10) . A solution of compound 9 (2.5g, 10.77 mmol) and 98% hydrazine monohydrate (0.65 g, 12.98 mmol) in ethanol (25 mL) was stirred for 4 h at room temperature. The solvent was removed under reduced pressure and the residue was taken up in water. 
Synthesis
(S)-11-Hydrazinyl-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5(11aH)-one
((13aS)-9-Oxo-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-3-yl)pivalamide (7a)
. To a solution of compound 11 (0.1 g, 0.39 mmol) and pyridine (0.2 mL, 2.48 mmol) in T (2 mL) was added pivaloyl chloride (0.058 mL, 47.05 mmol) dropwise at 0 °C. The mixture was stirred at 0 °C for 45 min and filtered. The filtrate was concentrated in vacuo, the residue was dissolved in ethyl acetate, washed sequentially with water and saturated sodium bicarbonate solution, dried over sodium sulfate and concentrated under reduced pressure to give compound 7a (0.086 g, 65% yiled) as an off-white solid. mp 213-215 °C; IR ν max 3296, 2957, 1687, 1630 cm 
General Procedure for Amide Coupling: Preparation of 7b-k
To a stirred solution of compound 11 (0.1 g, 0.39 mmol) and N,N-diisopropylethylamine (0.17 mL, 0.98 mmol) in N,N-dimethylformamide (2 mL) was added the appropriate carboxylic acid 12b-k (43.14 mmol) and 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (0.22 g, 0.59 mmol) at room temrature. The reaction mixture was heated at 50 °C for 15-45 min. The mixture was dissolved in ethyl acetate, washed sequentially with water and saturated sodium bicarbonate solution, dried over sodium sulfate and concentrated in vacuo. The crude product was purified by column chromatography (SiO 2 , 10-30% ethyl acetate/n-hexane). [1,2-a] [1, 2, 4] triazolo [3,4-c] [1, 4] [1,2-a] [1, 2, 4] triazolo [3,4-c] [1, 4] diazepin-3-yl)benzamide (7c). Yield 75%; white solid; mp 180-181 °C; IR ν max 3437, 1647, 1572, 1326, 827 cm Fluoro-N-((13aS)-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4 ]triazolo [3,4-c] [1, 4] diazepin-3-yl)benzamide (7d). Yield 80%; white solid; mp 159-160 °C; IR ν max 3437, 1640, 1579, 1342, 765 cm -9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e] pyrrolo [1,2-a] [1, 2, 4] triazolo [3,4- [1,2-a] [1, 2, 4] triazolo [3,4- -9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e] pyrrolo [1,2-a] [1, 2, 4] triazolo [3,4-c] [1, 4] -9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e] pyrrolo [1,2-a] [1, 2, 4] triazolo [3,4-c] [1, 4] diazepin-3-yl)benzamide (7h). Yield 65%; off-white solid; mp 175-177 °C; IR ν max 3434, 1642, 1565, 1335, 788 cm 12, 13, pyrrolo [1,2-a] [1, 2, 4] triazolo [3,4- 
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Biological Activity Test Procedures
Cell Culture
Human fibroblast cells (MRC-5) cells were used for cell culture experiments. Cells were cultured with 90% Eagle's minimum essential medium with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, 1.0 mM sodium pyruvate with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were placed in an incubator to maintain high humidity, 37 °C, and 5% CO 2 for the cell culture experiments. Cells were routinely sub-passaged in a 1:2 to 1:5 split using 0.25% trypsin. Human hepatocellular carcinoma (Mahlavu) epithelial cells were used for cell culture experiments. Cells were cultured with 90% Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were placed in an incubator to maintain high humidity, a temperature of 37 °C, and 5% CO 2 for cell culture experiments. Cells were routinely sub-passaged in a 1:4 to 1:6 split using 0.25% trypsin.
CCK-8 for Cell Proliferation Assay
The cell viability was determined using a CCK-8 assay following the manufacturer's instructions. Mahlavu cells and MRC-5 cells were seeded in 96-well plates and allowed to attach overnight at 37 °C. Cells were treated with PBDT-7a-k in 0.1% FBS MEM or DMEM (100 μL/well), and the cells were incubated for 48 h in a humidified atmosphere. After the incubation period, 10 μL of cell Counting Kit-8 solution was added to the medium, and the cells were incubated for an additional 1-4 h in the incubator. The absorbance at 450 nm was then measured using a microplate reader. The IR was calculated using the following equation: IR = [1 − (A value for the treated samples − A value for the blank samples)/(A value for the control samples − A value for the blank samples)] × 100%. The assays were performed in triplicate and repeated at least twice.
Conclusions
We have synthesized a series of novel amido-substituted triazolopyrrolo [2,1-c] [1, 4] benzodiazepines from isatoic anhydride in high total yields. The biological evaluation of these compounds based on the growth of Mahlavu and MRC-5 cells revealed that compound PBDT-7i selectively inhibited the proliferation of Mahlavu cells. More interestingly, compound PBDT-7i might inhibit not only Mahlavu cell growth, but also shows low toxicity towards MRC-5 cells.
